According to IMARC Group latest report titled “Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on biologics market size 2022. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global biologics market reached a value of US$ 294 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 501.9 Billion by 2027, exhibiting a CAGR of 9.25% during 2022-2027.
Biologics, also known as biological drugs, refer to disease-modifying antirheumatic drugs (DMARDs) comprised of components of living organisms. They include vaccines, blood, blood components, cells, genes, tissues, allergens, etc., derived from humans, animals, birds, insects, plants, microorganisms, etc. Biologics control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They are also utilized to treat various diseases and conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, etc.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Market Trends:
The increasing incidences and diagnosis of chronic diseases necessitating advanced diagnostics and treatment are primarily driving the biologics market. Besides this, government bodies of various countries are introducing initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of the coronavirus disease (COVID-19), which is further propelling the market growth. Moreover, scientists and researchers are extensively investigating species and expression systems to improve the productivity of biological products. Additionally, numerous pharmaceutical companies are undertaking research and development (R&D) activities to enhance the efficacy of oral products for rheumatoid arthritis and Crohn’s disease, which is expected to fuel the biologics market in the coming years.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market
Competitive Landscape with Key players:
The report has also analysed the competitive landscape of the market with some of the key players being.
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi
Biologics Market Segmentation:
Our report has categorized the market based on region, source, product, disease and manufacturing.
Breakup by Source:
- Microbial
- Mammalian
- Others
Breakup by Product:
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Antisense, RNAi and Molecular Therapy
- Others
Breakup by Disease:
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
Breakup by Manufacturing:
- Outsourced
- In-House
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
We are updating our reports, If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Competitive landscape, etc. Click request free sample report, the report will be delivered to you in PDF format via email within 24 to 48 hours after the payment confirmation.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800